Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | BHMT | Q93088 | 2/20 | 0.44 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233758 | 1.00 | ARG1 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL14418415 | 0.88 | NOS2 (0.50) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937851 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937848 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Alanine SCHEMBL9937853 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36935 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36934 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL29393779 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL7845774 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| SCHEMBL29378137 | 0.86 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. | 2022-05-12 | — | — | US | disclosed |
| EP-3937922-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113557014-A | Method for treating organic acidemia | 止血治疗有限公司 | 2021-10-26 | — | — | CN | disclosed |
| WO-2020186216-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | HEMOSHEAR THERAPEUTICS, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1144435-B1 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | disclosed |
| US-6407066-B1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1144435-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043413-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0180672-B1 | PROCESS FOR THE PRODUCTION OF FLAVOR ENHANCING SEASONINGS | AJINOMOTO CO., INC. (JP) | 1988-09-21 | — | — | EP | disclosed |
| US-4741914-A | WITH GLUTAMIC ACID SALT | AJINOMOTO CO., INC. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0180672-A1 | Process for the production of flavor enhancing seasonings | AJINOMOTO CO., INC. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ARG1 3338/4885ARG2 4380/4885NOS2 2609/4885 |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | ARG1 1222/4885ARG2 351/4885NOS2 1594/4885 |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | OTC, OAT, PCCA | ARG1 1103/4885ARG2 310/4885NOS2 770/4885 |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ARG1 1694/4885ARG2 1682/4885NOS2 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.